Cardiopulmonary exercise performance and factors associated with aerobic capacity in neuromuscular diseases.


Journal

Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146

Informations de publication

Date de publication:
12 2021
Historique:
revised: 14 09 2021
received: 31 12 2020
accepted: 16 09 2021
pubmed: 23 9 2021
medline: 19 3 2022
entrez: 22 9 2021
Statut: ppublish

Résumé

Aerobic deconditioning, due to lower levels of physical activity, could impact independence for people with neuromuscular conditions. We report the maximal cardiopulmonary response in a cohort of people with Charcot Marie Tooth disease type 1A (CMT 1A) and inclusion body myositis (IBM). We also explored potential predictors of aerobic capacity with measures of physical impairment and functional performance. Participants underwent maximal cardiopulmonary exercise testing (CPET) using a semi-recumbent cycle ergometer. Data were analyzed to determine the peak O Twenty-two people with CMT and 17 people with IBM were recruited. Both groups showed significantly lower VO Lower than predicted CPET variables were observed that were not explained by cardiopulmonary limitations or reduced effort, implicating peripheral factors in limiting the cycling task. Regression analysis implied prediction of VO2 peak by body fat percentage and 6-min walk distance. Six-minute walk distance could be a potential proxy measure of cardiopulmonary fitness.

Identifiants

pubmed: 34550609
doi: 10.1002/mus.27423
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

683-690

Subventions

Organisme : Department of Health
ID : PB-PG-0711-25151
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K000608/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0601943
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : U54 NS065712
Pays : United States

Informations de copyright

© 2021 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.

Références

Aitkens S, Kilmer DD, Wright NC, McCrory MA. Metabolic syndrome in neuromuscular disease. Arch Phys Med Rehabil. 2005;86:1030-1036.
Anens E, Emtner M, Hellström K. Exploratory study of physical activity in persons with Charcot-Marie-tooth disease. Arch Phys Med Rehabil. 2015;96:260-268.
Ramdharry GM, Pollard AJ, Grant R, et al. A study of physical activity comparing people with Charcot-Marie-tooth disease to normal control subjects. Disabil Rehabil. 2016;39:1753-1758.
World Health Organisation WHO. Physical Inactivity: A Global Public Health Problem. (2014). Accessed December 29, 2020. https://www.who.int/health-topics/physical-activity#tab=tab_2.
Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BGM, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007;62:571-579.
Carter GT, Abresch RT, Fowler WM Jr, Johnson ER, Kilmer DD, McDonald CM. Profiles of neuromuscular diseases. Hereditary motor and sensory neuropathy, types I and II. Am J Phys Med Rehabil. 1995;74:S140-S149.
Wiesinger GF, Quittan M, Nuhr M, et al. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil. 2000;81:1-5.
Wallace A, Pietrusz A, Dewar E, et al. Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity. Neurology. 2019;92:e1773-e1785.
Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705-713.
World Health Organisation. WHO | Global recommendations on physical activity for health. https://www.who.int/publications-detail-redirect/9789241599979. Accessed September 14, 2021.
American Thoracic Society & American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211-277.
Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol. 1986;60:2020-2027.
Pinkstaff S, Peberdy MA, Kontos MC, Finucane S, Arena R. Quantifying exertion level during exercise stress testing using percentage of age-predicted maximal heart rate, rate pressure product, and perceived exertion. Mayo Clin Proc. 2010;85:1095-1100.
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-tooth disease. J Peripher Nerv Syst. 2011;16:191-198.
Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L, The Muscle Study Group (MSG). Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008;37:473-476.
Krupp LB. Measurement of fatigue. Fatigue. Philadelphia, PA: Butterworth Heineman; 2003.
Graham RC, Hughes RAC. Clinimetric properties of a walking scale in peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2006;77:977-979.
Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381-1395.
Mulligan HF, Hale LA, Whitehead L, Baxter GD. Barriers to physical activity for people with long-term neurological conditions: a review study. Adapt Phys Activ Q. 2012;29:243-265.
Blackie S, Fairbarn MS, McElvaney NG, Wilcox PG, Morrison NJ, Pardy RL. Normal values and ranges for ventilation and breathing pattern at maximal exercise. Chest. 1991;100:136-142.
Sun X-G, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med. 2002;166:1443-1448.
Wasserman K. Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73:751-754.
Paterson DH, Govindasamy D, Vidmar M, Cunningham DA, Koval JJ. Longitudinal study of determinants of dependence in an elderly population. J Am Geriatr Soc. 2004;52:1632-1638.
Bassett DR, Howley ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc. 2000;32:70-84.
Howley E, Bassett D, Welch H. Criteria for maximal oxygen uptake: review and commentary. Med Sci Sports Exerc. 1995;27:1292-1301.
Morrow JM, Sinclair CDJ, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 2015;15:65-77. https://doi.org/10.1016/S1474-4422(15)00242-2
Schillings ML, Kalkman JS, Janssen HMHA, Van Engelen BGM, Bleijenberg G, Zwarts MJ. Experienced and physiological fatigue in neuromuscular disorders. Clin Neurophysiol. 2007;118:292-300.
Lindeman E, Spaans F, Reulen JP, Leffers P, Drukker J. Surface EMG of proximal leg muscles in neuromuscular patients and in healthy controls. Relations to force and fatigue. J Electromyogr Kinesiol. 1999;9:299-307.
Menotti F, Laudani L, Damiani A, Macaluso A. Amount and intensity of daily living activities in Charcot-Marie-tooth 1A patients. Brain Behav. 2014;4:14-20.
Mondal H, Mishra SP. Effect of BMI, body fat percentage and fat free mass on maximal oxygen consumption in healthy young adults. J Clin Diagn Res. 2017;11:CC17-CC20.
Egaña M, O'Riordan D, Warmington SA. Exercise performance and VO2 kinetics during upright and recumbent high-intensity cycling exercise. Eur J Appl Physiol. 2010;110:39-47.

Auteurs

Gita M Ramdharry (GM)

Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.
Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, University College Hospitals, NHS Foundation Trust, London, UK.

Amanda Wallace (A)

Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.

Philip Hennis (P)

Institute of Sport, Exercise and Health, UCL, London, UK.

Elizabeth Dewar (E)

Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, University College Hospitals, NHS Foundation Trust, London, UK.

Magdalena Dudziec (M)

Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.
Institute of Sport, Exercise and Health, UCL, London, UK.

Katherine Jones (K)

Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, University College Hospitals, NHS Foundation Trust, London, UK.

Aleksandra Pietrusz (A)

Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.

Mary M Reilly (MM)

Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.

Michael G Hanna (MG)

Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH